In a recent update, Morgan Stanley revised its price target for Alnylam Pharmaceuticals (ALNY, Financial), reducing it from $284 to $268 while maintaining an "Equal Weight" rating on the stock. This adjustment reflects the firm's cautious stance, as it anticipates sales figures for the TTR franchise in the first quarter to be slightly below market expectations.
The financial institution is directing its attention toward the initial launch performance of Amvuttra in the treatment of ATTR-CM. This focus comes as part of a broader analysis of upcoming earnings for small-to-mid cap biotechnology companies under the analyst's watch.
Alnylam's performance in this context will be crucial as investors look for signs of robust early market adoption for Amvuttra, a recently launched therapeutic poised to impact the company's growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 28 analysts, the average target price for Alnylam Pharmaceuticals Inc (ALNY, Financial) is $318.50 with a high estimate of $500.00 and a low estimate of $195.00. The average target implies an upside of 40.75% from the current price of $226.28. More detailed estimate data can be found on the Alnylam Pharmaceuticals Inc (ALNY) Forecast page.
Based on the consensus recommendation from 33 brokerage firms, Alnylam Pharmaceuticals Inc's (ALNY, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Alnylam Pharmaceuticals Inc (ALNY, Financial) in one year is $434.32, suggesting a upside of 91.94% from the current price of $226.28. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Alnylam Pharmaceuticals Inc (ALNY) Summary page.
